Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: Results of an International survey

Désirée Van Der Heijde, Joachim Sieper, Dirk Elewaut, Atulya (Atul) Deodhar, Aileen L. Pangan, Alexander P. Dorr

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Recognition, diagnosis, and management of axial spondyloarthritis (axial SpA) continue to advance.

Objectives: The objectives of this study were to compare referrals, diagnosis, and management of axial SpA in Western Europe (WE), North America (US and Canada), and the rest of world (RoW) in academic and community rheumatology practices and to identify areas for further education. Methods: Rheumatologists responded online to theMAXIMA (Management of Axial SpA International and Multicentric Approaches) survey. Questions pertained to referral, diagnosis, and management of axial SpA.

Results: Rheumatologists (N = 809) from 56 countries completed the survey about patients with chronic back pain (≥3 months) starting before age 45 years. Responses from academic and community practice rheumatologists were generally similar.Most referrals were fromprimary care providers. Symptom duration of 3 years or more at referral was reported more frequently by WE and RoW than US respondents. More WE and RoW than US rheumatologists referred to the Assessment of SpondyloArthritis International Society criteria for axial SpA in clinical practice. Rheumatologists reported prescribing disease-modifying antirheumatic drugs for the management of axial SpA. Sulfasalazine was frequently prescribed across regions; methotrexate was more commonly prescribed by US rheumatologists compared with other regions.

Conclusions: Referral patterns, diagnosis, and disease management for axial SpAwere similar amongWE, North America, and RoWrheumatologists and in academic/community practices, although more WE and RoW rheumatologists referred to Assessment of SpondyloArthritis International Society criteria in clinical practice. Disease-modifying antirheumatic drugs were commonly prescribed for axial SpA patients, although it was unclear whether these were prescribed for axial or peripheral symptoms.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalJournal of Clinical Rheumatology
Volume20
Issue number8
DOIs
StatePublished - Dec 11 2014

Fingerprint

Disease Management
Referral and Consultation
Antirheumatic Agents
North America
Sulfasalazine
Rheumatology
Back Pain
Rheumatologists
Surveys and Questionnaires
Methotrexate
Chronic Pain
Canada
Education

Keywords

  • Axial spondyloarthritis
  • Diagnosis
  • Disease management
  • Referral patterns
  • Survey

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis : Results of an International survey. / Van Der Heijde, Désirée; Sieper, Joachim; Elewaut, Dirk; Deodhar, Atulya (Atul); Pangan, Aileen L.; Dorr, Alexander P.

In: Journal of Clinical Rheumatology, Vol. 20, No. 8, 11.12.2014, p. 411-417.

Research output: Contribution to journalArticle

Van Der Heijde, Désirée ; Sieper, Joachim ; Elewaut, Dirk ; Deodhar, Atulya (Atul) ; Pangan, Aileen L. ; Dorr, Alexander P. / Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis : Results of an International survey. In: Journal of Clinical Rheumatology. 2014 ; Vol. 20, No. 8. pp. 411-417.
@article{74b053b5660e46fdaca12df2d3fa121e,
title = "Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis: Results of an International survey",
abstract = "Background: Recognition, diagnosis, and management of axial spondyloarthritis (axial SpA) continue to advance.Objectives: The objectives of this study were to compare referrals, diagnosis, and management of axial SpA in Western Europe (WE), North America (US and Canada), and the rest of world (RoW) in academic and community rheumatology practices and to identify areas for further education. Methods: Rheumatologists responded online to theMAXIMA (Management of Axial SpA International and Multicentric Approaches) survey. Questions pertained to referral, diagnosis, and management of axial SpA.Results: Rheumatologists (N = 809) from 56 countries completed the survey about patients with chronic back pain (≥3 months) starting before age 45 years. Responses from academic and community practice rheumatologists were generally similar.Most referrals were fromprimary care providers. Symptom duration of 3 years or more at referral was reported more frequently by WE and RoW than US respondents. More WE and RoW than US rheumatologists referred to the Assessment of SpondyloArthritis International Society criteria for axial SpA in clinical practice. Rheumatologists reported prescribing disease-modifying antirheumatic drugs for the management of axial SpA. Sulfasalazine was frequently prescribed across regions; methotrexate was more commonly prescribed by US rheumatologists compared with other regions.Conclusions: Referral patterns, diagnosis, and disease management for axial SpAwere similar amongWE, North America, and RoWrheumatologists and in academic/community practices, although more WE and RoW rheumatologists referred to Assessment of SpondyloArthritis International Society criteria in clinical practice. Disease-modifying antirheumatic drugs were commonly prescribed for axial SpA patients, although it was unclear whether these were prescribed for axial or peripheral symptoms.",
keywords = "Axial spondyloarthritis, Diagnosis, Disease management, Referral patterns, Survey",
author = "{Van Der Heijde}, D{\'e}sir{\'e}e and Joachim Sieper and Dirk Elewaut and Deodhar, {Atulya (Atul)} and Pangan, {Aileen L.} and Dorr, {Alexander P.}",
year = "2014",
month = "12",
day = "11",
doi = "10.1097/RHU.0000000000000180",
language = "English (US)",
volume = "20",
pages = "411--417",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Referral patterns, diagnosis, and disease management of patients with axial spondyloarthritis

T2 - Results of an International survey

AU - Van Der Heijde, Désirée

AU - Sieper, Joachim

AU - Elewaut, Dirk

AU - Deodhar, Atulya (Atul)

AU - Pangan, Aileen L.

AU - Dorr, Alexander P.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - Background: Recognition, diagnosis, and management of axial spondyloarthritis (axial SpA) continue to advance.Objectives: The objectives of this study were to compare referrals, diagnosis, and management of axial SpA in Western Europe (WE), North America (US and Canada), and the rest of world (RoW) in academic and community rheumatology practices and to identify areas for further education. Methods: Rheumatologists responded online to theMAXIMA (Management of Axial SpA International and Multicentric Approaches) survey. Questions pertained to referral, diagnosis, and management of axial SpA.Results: Rheumatologists (N = 809) from 56 countries completed the survey about patients with chronic back pain (≥3 months) starting before age 45 years. Responses from academic and community practice rheumatologists were generally similar.Most referrals were fromprimary care providers. Symptom duration of 3 years or more at referral was reported more frequently by WE and RoW than US respondents. More WE and RoW than US rheumatologists referred to the Assessment of SpondyloArthritis International Society criteria for axial SpA in clinical practice. Rheumatologists reported prescribing disease-modifying antirheumatic drugs for the management of axial SpA. Sulfasalazine was frequently prescribed across regions; methotrexate was more commonly prescribed by US rheumatologists compared with other regions.Conclusions: Referral patterns, diagnosis, and disease management for axial SpAwere similar amongWE, North America, and RoWrheumatologists and in academic/community practices, although more WE and RoW rheumatologists referred to Assessment of SpondyloArthritis International Society criteria in clinical practice. Disease-modifying antirheumatic drugs were commonly prescribed for axial SpA patients, although it was unclear whether these were prescribed for axial or peripheral symptoms.

AB - Background: Recognition, diagnosis, and management of axial spondyloarthritis (axial SpA) continue to advance.Objectives: The objectives of this study were to compare referrals, diagnosis, and management of axial SpA in Western Europe (WE), North America (US and Canada), and the rest of world (RoW) in academic and community rheumatology practices and to identify areas for further education. Methods: Rheumatologists responded online to theMAXIMA (Management of Axial SpA International and Multicentric Approaches) survey. Questions pertained to referral, diagnosis, and management of axial SpA.Results: Rheumatologists (N = 809) from 56 countries completed the survey about patients with chronic back pain (≥3 months) starting before age 45 years. Responses from academic and community practice rheumatologists were generally similar.Most referrals were fromprimary care providers. Symptom duration of 3 years or more at referral was reported more frequently by WE and RoW than US respondents. More WE and RoW than US rheumatologists referred to the Assessment of SpondyloArthritis International Society criteria for axial SpA in clinical practice. Rheumatologists reported prescribing disease-modifying antirheumatic drugs for the management of axial SpA. Sulfasalazine was frequently prescribed across regions; methotrexate was more commonly prescribed by US rheumatologists compared with other regions.Conclusions: Referral patterns, diagnosis, and disease management for axial SpAwere similar amongWE, North America, and RoWrheumatologists and in academic/community practices, although more WE and RoW rheumatologists referred to Assessment of SpondyloArthritis International Society criteria in clinical practice. Disease-modifying antirheumatic drugs were commonly prescribed for axial SpA patients, although it was unclear whether these were prescribed for axial or peripheral symptoms.

KW - Axial spondyloarthritis

KW - Diagnosis

KW - Disease management

KW - Referral patterns

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=84916597415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916597415&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000180

DO - 10.1097/RHU.0000000000000180

M3 - Article

C2 - 25417676

AN - SCOPUS:84916597415

VL - 20

SP - 411

EP - 417

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 8

ER -